Opendata, web and dolomites

MATURE-NK SIGNED

MAnufacturing of TUmour-REactive Natural Killer cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MATURE-NK project word cloud

Explore the words cloud of the MATURE-NK project. It provides you a very rough idea of what is the project "MATURE-NK" about.

immunotechnology    biology    receptors    receptor    comprise    link    modules    exchange    building    trials    competences    inhibitory    student    bioinformatics    portfolios    medicine    sectors    reactivity    winter    cross    refractory    mouse    designed    therapeutic    checkpoint    bridge    modulation    biotech    ligand    activated    diseases    protocol    trial    compliant    manipulated    evaluation    cancer    incurable    property    manufacturing    donor    ligands    pioneering    medicinal    inhibitors    translational    clinical    humanized    schools    modification    treatment    car    therapies    recipient    groups    rights    classified    nk    anti    unknown    gmp    genetically    gap    train    chimeric    personalized    natural    blocking    network    combine    companies    oriented    fortify    first    training    cells    combination    summer    industry    activating    bispecifc    tumor    killer    intellectual    translate    antibody    antigen    experts    cell    atmps    business    models    interactions    therapy    basic    reagents    private   

Project "MATURE-NK" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE HOCHSCHULE HANNOVER 

Organization address
address: Carl-Neuberg-Strasse 1
city: HANNOVER
postcode: 30625
website: www.mh-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙351˙662 €
 EC max contribution 3˙351˙662 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 249˙216.00
2    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 286˙275.00
3    UNIVERSITAT BASEL CH (BASEL) participant 265˙226.00
4    INNATE PHARMA FR (MARSEILLE) participant 262˙875.00
5    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 262˙875.00
6    THE HEBREW UNIVERSITY OF JERUSALEM IL (JERUSALEM) participant 260˙300.00
7    IRCCS OSPEDALE POLICLINICO SAN MARTINO IT (GENOVA) participant 258˙061.00
8    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 255˙934.00
9    GLYCOSTEM-THERAPEUTICS B.V. NL (OSS) participant 255˙374.00
10    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 249˙216.00
11    MILTENYI BIOTEC GMBH DE (BERGISH GLADBACH) participant 249˙216.00
12    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) participant 249˙216.00
13    UNIVERSIDAD POMPEU FABRA ES (BARCELONA) participant 247˙872.00

Map

 Project objective

'This project will provide future-oriented translational research training designed to bridge the gap between basic research and applied development of new cell-based therapeutic products by the biotech industry and their clinical use for incurable diseases. This will be done on the example of activated/genetically manipulated natural killer (NK) cells, which are classified as Advanced Therapy Medicinal Products ('ATMPs'), and their use in treatment of cancer refractory to classical therapies. For this we combine experts in NK cell biology supported by bioinformatics, clinical groups pioneering NK cell therapies and biotech companies with NK cell-based portfolios. A student exchange will ensure training in basic, clinical and private sectors. Network-wide training modules organized in summer/winter schools include immunotechnology, business management and intellectual property rights. This will train competences important to translate research findings to personalized medicine. In research we build on information from clinical trials of NK cell-based therapies. We will improve anti-tumor reactivity of NK cells including selection of NK subsets and modulation of NK receptor/ligand interactions. First, this will comprise i) improved donor/recipient combination and NK subsets and ii) modification of NK cells by chimeric antigen receptors ('CAR') and bispecifc antibody reagents to cross-link NK cells to tumor targets. Second, it will fortify NK cell reactivity by i) blocking ligand interactions of inhibitory receptors ('checkpoint inhibitors') and ii) defining unknown ligands of activating NK receptors on tumor cells. Third, procedures and NK products in their best combination will be developed by i) evaluation in humanized mouse models, ii) building a GMP-compliant manufacturing process and iii) design of a clinical trial protocol. The project should provide for manufacturing of NK cell-based therapeutic products and their evaluation in clinical trials. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MATURE-NK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MATURE-NK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

AIMed (2020)

Antimicrobial Integrated Methodologies for orthopaedic applications

Read More